Antibodies directed against IL-17
US9328166B2 · kind B2 · utility
0Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2011 |
| Grant date | May 3, 2016 |
| Priority date | — |
| Expiry date | Aug 2, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an isolated interleukin-17 (IL-17)-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 78, or SEQ ID NO: 79, and an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The invention also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.